Latest Conference Articles

May 16th 2015, 1:05pm

AUA Annual Meeting

Use of multiparametric MRI as follow-up to a suggestive PSA test or digital rectal exam reduced prostate biopsies by 73% but identified fewer prostate cancers compared with upfront transrectal ultrasound–guided biopsy, a decision-tree analysis showed.

May 16th 2015, 12:22pm

AUA Annual Meeting

The role of androgen receptor variant-7 in patients with early stage prostate cancer is not well characterized but data presented at the 2015 American Urological Association (AUA) Meeting is bringing the discussion into focus.

May 16th 2015, 9:23am

AUA Annual Meeting

Alexander Kutikov, MD, FACS, attending surgeon, urologic oncology, associate professor, urologic oncology, Fox Chase Cancer Center, discusses the understanding of tumor pathology in renal cell carcinoma.

May 16th 2015, 7:23am

AUA Annual Meeting

E. David Crawford, MD, professor, urology, radiation oncology, University of Colorado Denver, discusses the differences between an LHRH agonist and a GNRH antagonist.

May 13th 2015, 1:09pm

ASCO Annual Meeting

Adding elotuzumab to lenalidomide (Revlimid) and dexamethasone reduced the risk of disease progression by 30% in patients with relapsed/refractory multiple myeloma.

May 13th 2015, 1:06pm

ASCO Annual Meeting

The addition of docetaxel to standard hormonal therapy significantly improved survival among men with newly diagnosed, hormone-naïve advanced prostate cancer.

May 13th 2015, 1:00pm

ASCO Annual Meeting

For those with a history of non-melanoma skin cancer, reducing their risk of recurrence can be as simple as taking the vitamin B3 pill nicotinamide.

May 13th 2015, 1:00pm

ASCO Annual Meeting

Treatment with an intensified chemotherapy regimen was associated with improvements in event-free survival for children with favorable histology Wilms tumor with loss of heterozygosity in chromosomes 1p and 16q.

May 7th 2015, 7:57am

MDS Symposium

Guillermo Garcia-Manero, MD, chief, Section of Myelodysplastic Syndromes, deputy chair, Translational Research, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses deferasirox (Exjade) in iron chelation therapy for patients with myelodysplastic syndromes (MDS).

May 2nd 2015, 11:42am

MDS Symposium

Treatment with the thrombopoietin receptor agonist eltrombopag significantly improved cytopenias and was well-tolerated in patients with low to intermediate-2 risk myelodysplastic syndromes.

May 2nd 2015, 8:05am

MDS Symposium

A biomarker model that incorporates the mutational status of multiple somatic genes could be used to predict response to hypomethylating agents for patients with myelodysplastic syndromes.

May 2nd 2015, 6:44am

MDS Symposium

Serum erythropoietin levels and risk by IPSS were predictive of response to erythropoiesis-stimulating agents in patients with myelodysplastic syndromes.

May 2nd 2015, 5:25am

MDS Symposium

Gail J. Roboz, MD, associate professor of Medicine, director, Leukemia Program, Weill Medical College of Cornell University, New York-Presbyterian Hospital, discusses the growing field of molecular mutations in myelodysplastic syndromes (MDS).

May 2nd 2015, 5:11am

MDS Symposium

Amer Zeidan, MBBS, MHS, assistant professor of Medicine, Hematology, Yale Cancer Center, discusses a population-based study of subsequent myelodysplastic syndromes (MDS) in prostate cancer patients after radiotherapy.

May 1st 2015, 12:39pm

MDS Symposium

Treatment with T-cell depleted transplantation was associated with a lower incidence of acute graft versus host disease (GVHD) and a very low incidence of chronic GVHD compared with unmodified allografts in patients with advanced myelodysplastic syndrome.

May 1st 2015, 11:20am

MDS Symposium

Treatment with lenalidomide (Revlimid) versus placebo improved health-related quality of life (HRQoL) after 24 weeks for patients with myelodysplastic syndromes.

May 1st 2015, 7:23am

MDS Symposium

Treatment strategies for patients with myelodysplastic syndromes are built upon a foundation of supportive care, which consists of transfusions, iron chelation, and growth factor therapy.

May 1st 2015, 6:15am

MDS Symposium

Sara M. Tinsley, MS, PhD, ARNP, AOCN, nurse practitioner, malignant hematology, Moffitt Cancer Center, discusses a study that examined quality of life in patients with high-risk myelodysplastic syndromes (MDS).

May 1st 2015, 5:30am

MDS Symposium

Rami S. Komrokji, MD, clinical director, Department of Malignant Hematology, H. Lee Moffitt Cancer Center, discusses a study that examined risk stratification of therapy-related MDS.

April 30th 2015, 1:22pm

MDS Symposium

OncLive spoke with Guillermo Garcia-Manero, MD, regarding the significance of sotatercept and rigosertib and their potential as therapies in MDS.